BRIEF-Apogee Therapeutics Announces Positive 16-Week Part B Induction Dose Optimization Results From Phase 2 Apex Trial Of Zumilokibart In Moderate-To-Severe Atopic Dermatitis

Apogee Therapeutics, Inc.

Apogee Therapeutics, Inc.

APGE

0.00

May 27 (Reuters) - Apogee Therapeutics Inc APGE.O:

  • APOGEE THERAPEUTICS ANNOUNCES POSITIVE 16-WEEK PART B INDUCTION DOSE OPTIMIZATION RESULTS FROM PHASE 2 APEX TRIAL OF ZUMILOKIBART IN MODERATE-TO-SEVERE ATOPIC DERMATITIS

  • APOGEE THERAPEUTICS INC - TO ADVANCE MID-DOSE ZUMILOKIBART TO PHASE 3 TRIALS IN AD IN 2H 2026

  • APOGEE THERAPEUTICS INC - ZUMILOKIBART SHOWS FAVORABLE SAFETY PROFILE CONSISTENT WITH CLASS

  • APOGEE THERAPEUTICS INC - ANNOUNCES STRATEGIC FINANCING COLLABORATION WITH BLACKSTONE LIFE SCIENCES

  • APOGEE THERAPEUTICS INC - PHASE 2 APEX CLINICAL TRIAL MET ITS PRIMARY AND SECONDARY ENDPOINTS

Source text: ID:nGNX1x2xJC

Further company coverage: APGE.O


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.